The observed trend toward less stroke risk with GLP1-RAs use perhaps might be explained by the fact that GLP1 receptors are expressed in a wider range of the body, such as the brain, the heart (Ban et al., 2008), and the pancreas (Darsalia et al., 2015), and that GLP1-RAs, unlike DPP4-Is, cross the blood–brain barrier. Here, DPP4 is linked to stroke disorder.